A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1 –3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses

ConclusionsThe RP2D is tolerable and has preliminary activity in recurrent women ’s cancers. A phase 2 expansion study is now enrolling for recurrent ovarian cancer patients.Trial registrationClinicalTrials.gov identifier:NCT02484404. Registered June 29, 2015.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research